MU Department of Medicine 2011-2013 Annual Report Feb. 2014

2011-2013 Endocrinology cont. Principal Investigator REWIND: H9X-MC-GBDJ – The effect of LY2189265 on major cardiovascular events in patients with type 2 diabetes, Eli Lilly and Company, $4,100, 11/28/2011 to 10/31/2018 Principal Investigator TAKEDA 875: Phase 3 Study to Evaluate Cardiovascular Outcomes of TAK-875, 50 mg in Addition to Standard of Care in Subjects with Type 2 Diabetes and with Cardiovascular Disease or Multiple Risk Factors for Cardiovascular Events, Takeda Pharmaceuticals USA, Inc., $223,832, 02/01/2013 to 01/31/2014 Principal Investigator QUOTIENT: Reproducibility and Method Comparison Studies of the Quo-Test A1C System and the Quo-Lab A1C Test and CLIA Waiver Study of the Quo-Test A1C System, QUOTIENT DIAGNOSTICS, $75,493, 09/03/2013 to 09/02/2015 Principal Investigator Evaluation of the DPP-4 Inhibitor Sitagliptin in the Treatment of Non-Alcoholic Fatty Liver Disease Using In Phase and Out of Phase MRI, Pilot Study Award, MU Internal Medicine Research Council, $14,000, 05/01/2013 to 04/30/2014 Javad Habibi, MD Co-Principal Investigator Impact of direct renin inhibition and AT1R blockade on cardiovascular and renal abnormalities associated with insulin resistance in Ren2 rats: a combitorial strategy that targets the cardiometabolic syndrome, Novartis Pharmaceutical Corporation, $754,964, 02/01/2010 to 04/30/2012 Co-Investigator Comparison of Azilsartan Meoximil and Olemsartan on aldosterone breakthrough in hypert ensive rats during chronic Ang II infusion, Takeda Pharmaceuticals USA Inc., $274,149, 02/01/2011 to 10/31/2012 Department of Medicine 57 Co-Principal Investigator Guido Lastra, MD Ang II and overnutrition and insulin Principal Investigator resistance in cardiovascular tissue, Over-nutrition and obesity contribute NIH/NHLBI, $743,062, 04/11/2011 to to beta cell dysfunction through 03/31/2013 mTOR/S6K1activation, insulin resistance and IRS-1 and IRS-2 Principal Investigator degradation. Pilot Study Award, MU Impact of MK-0626 on renal proximal Internal Medicine Research Council, tubule integrity and sodium excretion $12,500, 05/01/2012 to 04/30/2013 in murine models of early diabetes, Merck and Co, Inc., $250,092, Camila Manrique, MD 08/31/2011 to 08/30/2013 Co-Investigator Comparison of Azilsartan Meoximil Co-Investigator and Olemsartan on Aldosterone Interactions of the RAAS and a western breakthrough in hypertensive rats diet on insulin metabolic actions, during chronic Ang II infusion, Takeda BLR&D Merit Review Award, $650,000, Pharmaceuticals USA Inc., $274,149, 10/01/2012 to 09/30/2016 02/01/2011 to 10/31/2012 Melvin R. Hayden, MD Principal Investigator Co-Principal Investigator Estrogen protects against chronic Impact of direct renin inhibition and over-nutrition induced skeletal muscle AT1R blockade on cardiovascular and vasculature dysfunction, Pilot Study renal abnormalities associated with Award, MU Internal Medicine Research insulin resistance in Ren2 rats: a Council, $12,500, 05/01/2012 to combitorial strategy that targets the 04/30/2013 cardiometabolic syndrome, Novartis Pharmaceutical Corporation, $754,964, James Sowers, MD 02/01/2010 to 04/30/2012 Principal Investigator Interactions of the RAAS and a western Uzma Khan, MD diet on insulin metabolic actions, Principal Investigator BLR&D Merit Review Award, $650,000, EISAI E7080: Phase II, multicenter, 10/01/2012 to 09/30/2016 open-label, single arm trial to evaluate the safety and efficacy of oral E7080 in Principal Investigator medullary and iodine-131 refractory, Ang II and overnutrition and insulin unresectable differentiated thyroid resistance in cardiovascular tissue, cancers, stratified by histology, Eisai NIH/NHLBI, $743,062, 04/11/2011 to Co, Ltd., $35,303, 12/01/2008 to 03/31/2013 02/28/2014 Principal Investigator Lilamani Kurukulasuriya, MD Ang II and aldosterone effects on Principal Investigator insulin resistance in cardiovascular PFIZER: A phase 3B multicenter, tissue, NIH/NHLBI, $1,256,850, double-blind, randomized withdrawal 05/01/2009 to 02/28/2013 efficacy and safety study of Pregabalin in the treatment of patients with Principal Investigator inadequately treated painful diabetic Impact of Saxagliptin Therapy on peripheral neuropathy, Pfizer Inc., Angiotensin II-dependent Salt- $10,657, 06/29/2010 to 06/28/2013 sensative Hypertension, Bristol Myers Squibb, $268,096. 03/01/2013 to Principal Investigator AZOR plus HCTZ clinical trial with Daiichi Sankyo, Daiichi Pharmaceuticals Corporation, $46,250, 08/27/2008 to 07/31/2013 02/28/2014

MU Department of Medicine 2011-2013 Annual Report Feb. 2014 | Page 57